November 2023 in “British Journal of Dermatology” Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
September 2023 in “Journal of The American Academy of Dermatology” The document's conclusion cannot be provided because the content is not available.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
January 2024 in “Acta dermato-venereologica”